Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | FAAH | O00519 | 6/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | STK4 | Q13043 | 1/20 | 0.33 |
| ▸ | STK3 | Q13188 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785559 | 0.90 | MPL (0.39) | MPLCNR2GRM5FAAHKMO | |
| SCHEMBL16776376 | 0.88 | POLB (0.41) | CNR2GRM5FAAHKMOALDH1A1 | |
| SCHEMBL19699054 | 0.83 | MPL (0.39) | MPLCNR2GRM5FAAHKMO | |
| SCHEMBL16776379 | 0.82 | WNT1 (0.39) | CNR2GRM5 | |
| SCHEMBL16776393 | 0.81 | AR (0.34) | MPLFAAH | |
| SCHEMBL16775913 | 0.79 | MPL (0.42) | MPLCNR2GRM5FAAHKMO | |
| SCHEMBL17618739 | 0.78 | GRM5 (0.42) | MPLCNR2GRM5FAAHALDH1A1 | |
| SCHEMBL16776307 | 0.78 | CNR2 (0.36) | CNR2FAAHKMO | |
| SCHEMBL19670657 | 0.76 | MPL (0.42) | MPLCNR2GRM5FAAHKMO | |
| SCHEMBL19670357 | 0.76 | MPL (0.41) | MPLCNR2GRM5FAAHUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MPL 3547/4885CNR2 2514/4885GRM5 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.